Clinical Trial Portfolios: A Critical Oversight in Human Research Ethics, Drug Regulation, and Policy
Regulators rely on clinical trials for drug approval and labeling decisions. Health systems and clinicians rely on the evidence from trials to determine treatment, and patients rely on it to decide which courses of care to undertake. Many of these stakeholders presume that the careful review of indi...
| Κύριοι συγγραφείς: | ; |
|---|---|
| Τύπος μέσου: | Ηλεκτρονική πηγή Άρθρο |
| Γλώσσα: | Αγγλικά |
| Έλεγχος διαθεσιμότητας: | HBZ Gateway |
| Interlibrary Loan: | Interlibrary Loan for the Fachinformationsdienste (Specialized Information Services in Germany) |
| Έκδοση: |
2019
|
| Στο/Στη: |
The Hastings Center report
Έτος: 2019, Τόμος: 49, Τεύχος: 4, Σελίδες: 31-41 |
| Διαθέσιμο Online: |
Volltext (lizenzpflichtig) Volltext (lizenzpflichtig) |
MARC
| LEADER | 00000naa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1937529282 | ||
| 003 | DE-627 | ||
| 005 | 20251002055613.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 251002s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/hast.1034 |2 doi | |
| 035 | |a (DE-627)1937529282 | ||
| 035 | |a (DE-599)KXP1937529282 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 1 |2 ssgn | ||
| 100 | 1 | |a London, Alex John |e VerfasserIn |4 aut | |
| 109 | |a London, Alex John | ||
| 245 | 1 | 0 | |a Clinical Trial Portfolios: A Critical Oversight in Human Research Ethics, Drug Regulation, and Policy |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Regulators rely on clinical trials for drug approval and labeling decisions. Health systems and clinicians rely on the evidence from trials to determine treatment, and patients rely on it to decide which courses of care to undertake. Many of these stakeholders presume that the careful review of individual studies is enough to address the ethical and scientific questions that arise in clinical trials. In what follows, however, we demonstrate that explicit consideration of trial portfolios—series of trials that are interrelated by a common set of objectives—is crucial. the ethical acceptability and evidentiary probity of individual trials can change depending on the characteristics of the portfolios in which they are embedded. Second, how trial portfolios are composed, how well they are coordinated, and how efficiently they use information determines the balance of risks and benefits they present as well as their different prospects for generating socially valuable information; these three factors also raise distinct questions of justice. | ||
| 601 | |a Portfolio | ||
| 700 | 1 | |a Kimmelman, Jonathan |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |a Hastings Center |t The Hastings Center report |d Malden, Mass. : Wiley, 1971 |g 49(2019), 4, Seite 31-41 |h Online-Ressource |w (DE-627)341346551 |w (DE-600)2067369-3 |w (DE-576)258761822 |x 1552-146X |7 nnas |
| 773 | 1 | 8 | |g volume:49 |g year:2019 |g number:4 |g pages:31-41 |
| 856 | 4 | 0 | |u https://doi.org/10.1002/hast.1034 |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1002/hast.1034 |x Verlag |z lizenzpflichtig |3 Volltext |
| 912 | |a NOMM | ||
| 935 | |a mteo | ||
| 951 | |a AR | ||
| ELC | |a 1 | ||
| ITA | |a 1 |t 1 | ||
| LOK | |0 000 xxxxxcx a22 zn 4500 | ||
| LOK | |0 001 4779655463 | ||
| LOK | |0 003 DE-627 | ||
| LOK | |0 004 1937529282 | ||
| LOK | |0 005 20251002055613 | ||
| LOK | |0 008 251002||||||||||||||||ger||||||| | ||
| LOK | |0 035 |a (DE-Tue135)IxTheo#2025-09-26#368A634FFED298BBFFB8494F035E587A9AFC1B9F | ||
| LOK | |0 040 |a DE-Tue135 |c DE-627 |d DE-Tue135 | ||
| LOK | |0 092 |o n | ||
| LOK | |0 852 |a DE-Tue135 | ||
| LOK | |0 852 1 |9 00 | ||
| LOK | |0 935 |a ixrk |a ixzs |a zota |a tiep | ||
| ORI | |a TA-MARC-ixtheoa001.raw | ||
